Genetic polymorphisms of interleukin-1-beta in association with sustained response to anti-viral treatment in chronic hepatitis B in Chinese
Article first published online: 1 JUN 2006
Alimentary Pharmacology & Therapeutics
Volume 23, Issue 12, pages 1703–1711, June 2006
How to Cite
CHAN, H. L.-Y., TSE, A. M.-L., ZHANG, M.-D., WONG, V. W.-S., CHIM, A. M.-L., HUI, A. Y. and SUNG, J. J.-Y. (2006), Genetic polymorphisms of interleukin-1-beta in association with sustained response to anti-viral treatment in chronic hepatitis B in Chinese. Alimentary Pharmacology & Therapeutics, 23: 1703–1711. doi: 10.1111/j.1365-2036.2006.02948.x
- Issue published online: 1 JUN 2006
- Article first published online: 1 JUN 2006
- Publication data Submitted 15 February 2006 First decision 6 March 2006 Resubmitted 10 March 2006 Resubmitted 28 March 2006 Accepted 30 March 2006
Interleukin-1β is a pro-inflammatory cytokine that may influence host defence against viral infection.
To investigate the impact of interleukin-1β gene polymorphism on the response to anti-viral treatment.
Hepatitis B e antigen-positive chronic hepatitis B patients who have completed a randomized study of peginterferon alpha-2b and lamivudine combination vs. lamivudine monotherapy were included. Sustained responders were patients who had persistent hepatitis B e antigen loss and less than two occasions with hepatitis B virus DNA >100 000 copies/mL at any time up to week 76 post-treatment. Polymorphisms at interleukin-1β-511, -31 and -3954 and interleukin-1 receptor antagonist (RN) were studied.
Eighty-eight patients were studied and 18 (20%) patients developed sustained response. Near complete linkage disequilibrium was observed between interleukin-1β-511 and -31 loci. After adjustment for the potential confounding effects of treatment allocation, hepatitis B virus genotype, pre-treatment alanine aminotransferase and hepatitis B virus DNA levels, genotype C/T at interleukin-1β-511 was found to be associated with higher sustained response than genotype C/C (adjusted odds ratio 10.4, 95% CI 1.1, 96.9, P = 0.040). The proportion of sustained responders tend to be higher among patients with allele T at interleukin-1β-511 (83%) than those without (70%) (P = 0.058).
High interleukin-1β production genotype at position -511 has a favourable response to anti-viral treatments.